According to filings with the U.S. Securities and Exchange Commission, LumaCyte is raising $12,999,991.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Sean Hart played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About LumaCyte
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis and sorting instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary technology utilizes Laser Force Cytology (LFC) to measure optical and fluidic forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell. The multivariate nature of the data has enabled a host of Big Data strategies and cloud computing capabilities that drive advanced analytics, allowing a deeper understanding of cell based biological systems. Applications of LumaCytes label-free platform technology include viral infectivity for vaccine development and manufacturing, cell and gene therapy development and production monitoring, cancer biology R&D, CAR T-cell immunotherapy, iPSCs, infectious disease, and pre-clinical drug discovery, in addition to multiple applications across the biomanufacturing sector for quality control and process optimization.

To learn more about LumaCyte, visit http://www.lumacyte.com/

Contact:
Sean Hart, Chief Executive Officer
888-472-9295
https://www.linkedin.com/in/seanjhart/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.